In a remarkable turn of events, Avinger, Inc., a renowned medical device company, witnessed a remarkable surge in its stock shares following the highly anticipated release of its cutting-edge Tigereye ST image-guided chronic total occlusion (CTO) crossing system. The announcement sent shockwaves through the market as the company’s shares skyrocketed by an impressive 64% to reach $6.79. This groundbreaking launch unfolded simultaneously in the United States and Germany, propelling Avinger’s stock to experience a staggering premarket surge of 53.15%.
The Tigereye ST system, after obtaining FDA 510(k) clearance on April 26, 2023, proved to be a game-changer for Avinger. Its successful commercial launch, coupled with the regulatory approval, played a pivotal role in the remarkable surge in the company’s shares. Specifically designed to aid physicians in navigating chronic total occlusions, which are complete arterial blockages, during peripheral vascular procedures, the Tigereye ST system has revolutionized the field.
It is worth noting that Avinger had previously initiated a limited release of the Tigereye system in the fourth quarter of 2020, but it was the full commercial launch that took place in January 2021 that truly solidified its impact. With its advanced imaging capabilities and unparalleled navigation features, the Tigereye ST system has become an invaluable asset for physicians conducting CTO crossing procedures.
Avinger, Inc.
AVGR
Buy
Updated on: 07/12/2023
Financial Health
Healthy
Debt to equity ratio: Strong Buy
Price to earnings ratio: Neutral
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
AVGR Stock Performance: Decrease in Value on September 18, 2023 with Positive Earnings Growth
On September 18, 2023, the stock performance of Avinger, Inc. (AVGR) showed significant movement. The previous close for AVGR was $4.07, and the stock opened at $6.30. Throughout the day, the stock had a range of $6.01 to $8.46. The trading volume for the day was 956,362, which was higher than the average volume of 6,737 over the past three months. AVGR has a market cap of $3.0M.
In terms of earnings growth, AVGR had a positive performance. The earnings growth for the last year was +4.63%, indicating a slight increase. However, the earnings growth for this year showed a significant improvement, with a growth rate of +98.15%. Looking ahead, the projected earnings growth for the next five years is +15.00%.
On the other hand, AVGR experienced a decline in revenue growth. The revenue growth for the last year was -18.33%, suggesting a decrease in the company’s revenue. Despite this, AVGR has a positive outlook for earnings growth in the coming years.
AVGR’s financial ratios provide further insight into its performance. The P/E ratio is not available (NM), indicating that the company may not have positive earnings or that the earnings are not sufficient to calculate the ratio. The price/sales ratio is 0.82, which suggests that the stock is relatively undervalued compared to its revenue. The price/book ratio is 0.52, indicating that the stock is undervalued based on its book value.
In terms of the stock’s performance on September 18, 2023, AVGR experienced a decrease in value. The stock price dropped by $0.05, which represents a percentage change of -10.19%. This decline in value may have been influenced by several factors, including market conditions and investor sentiment.
It is important to note that AVGR operates in the health technology sector, specifically in the medical specialties industry. The company is headquartered in Redwood City, California. However, no executives were listed in the available information.
Looking ahead, AVGR’s next reporting date is November 8, 2023. Analysts forecast an EPS (earnings per share) of -$0.22 for this quarter. The annual revenue for the last year was $8.3M, while the company reported a net loss of -$17.6M. The net profit margin for AVGR was -213.02%, indicating that the company’s expenses exceeded its revenue.
In conclusion, AVGR’s stock performance on September 18, 2023, showed a decrease in value. However, the company has experienced positive earnings growth in recent years, although it faced a decline in revenue growth. Investors should closely monitor AVGR’s financial performance and industry trends to make informed investment decisions.
AVGR Stock Shows Positive Performance with Analysts Forecasting Significant Increase
AVGR stock had a positive performance on September 18, 2023, as indicated by the 12-month price forecasts provided by analysts. According to data from CNN Money, the one analyst offering price forecasts for Avinger Inc has a median target of $24.00, with a high estimate and low estimate also at $24.00. This median estimate represents a significant increase of 223.89% from the last price of $7.41.
The consensus among investment analysts is to buy stock in Avinger Inc. This rating has remained steady since April, indicating a continued positive sentiment towards the company’s prospects. Investors are likely optimistic about the potential growth and performance of AVGR stock.
Avinger Inc reported earnings per share of -$0.22 for the current quarter. This suggests that the company incurred a loss during this period. However, it is important to note that earnings per share can fluctuate, and investors should consider other factors when evaluating the company’s financial health.
Avinger Inc reported $2.5 million in sales for the current quarter. While this figure may seem relatively low, it is essential to consider the context and industry benchmarks when assessing the company’s performance.
Investors should also take note of the reporting date for Avinger Inc’s financial results, which is scheduled for November 8. This date provides an opportunity for investors to gain further insights into the company’s financial performance and make informed investment decisions.
Overall, AVGR stock had a positive performance on September 18, 2023, with analysts forecasting a significant increase in the stock price. The consensus among investment analysts is to buy stock in Avinger Inc, indicating a positive sentiment towards the company’s prospects. However, investors should consider other factors, such as financial performance and industry trends, before making investment decisions.
Discussion about this post